



MAYNE PHARMA STRENGTHENS BOARD WITH NEW DIRECTOR

30 May 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Frank Condella has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately.

Mr Condella, a US resident, has over 30 years of experience in senior executive roles in the global pharmaceutical industry. Most recently, he was President and Chief Executive Officer of Juniper Pharmaceuticals (NASDAQ: JNP), a specialty pharmaceutical company based in Boston focused on developing women's health therapeutics and providing contract development services to clients, a position he held from 2009 until 2016.

Previously, he was Chief Executive Officer of Skyepharma plc, President of European operations at IVAX (now part of Teva), Chief Executive Officer of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products unit of American Home Products (Pfizer).

Mayne Pharma Chairman, Mr Roger Corbett, AO said "I am extremely pleased that Frank Condella has accepted the appointment to the Mayne Pharma Board. Frank brings a wealth of global healthcare and pharmaceutical industry experience to the Board that will be of great value to Mayne Pharma. Frank has extensive experience with advanced drug delivery technologies, developing and commercialising specialty and generic pharmaceuticals and providing contract development and manufacturing services from his time at Juniper, Skyepharma, IVAX, Faulding and Roche."

"As previously foreshadowed at the 2017 Annual General Meeting, the appointment of Frank follows a comprehensive external process to identify a new non-executive director based in the US with strong skills and experience in the US pharmaceutical industry. Frank has a substantial network of contacts across the biotechnology and pharmaceutical industry which will complement the existing talent in the organisation. We welcome him to the Board and look forward to his contribution to Mayne Pharma's growth."

In addition to his extensive management experience, Mr Condella has broad experience at board level and is currently Vice Chairman of Vectura Group plc and a Director of Palladio Biosciences Inc. Previously, he served as Chairman of Skyepharma plc and was a Director of Prosonix Ltd, Juniper Pharmaceuticals, Inc. and Fulcrum Pharma plc.

He has an MBA from D'Amore-McKim School of Business and a Bachelor of Science in Pharmacy from Bouvé College of Health Sciences at Northeastern University in the US.



ASX Announcement

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including potent compounds, controlled substances, modified-release products and inherently unstable compounds.